SCHEMBL4473340

SCHEMBL4473340

COc1cc2nccc(Oc3ccc(NC(=O)NC(C)c4nccs4)cc3F)c2cc1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 15/20 0.68
FLT3 P36888 4/20 0.68
PDGFRA P16234 3/20 0.68
KDR P35968 3/20 0.68
AXL P30530 2/20 0.68
BMPR1B O00238 1/20 0.68
PLK4 O00444 1/20 0.68
AURKA O14965 1/20 0.68
GAK O14976 1/20 0.68
EPHB6 O15197 1/20 0.68
RIPK2 O43353 1/20 0.68
STK10 O94804 1/20 0.68
ABL1 P00519 1/20 0.68
EGFR P00533 1/20 0.68
LCK P06239 1/20 0.68
FYN P06241 1/20 0.68
CSF1R P07333 1/20 0.68
YES1 P07947 1/20 0.68
LYN P07948 1/20 0.68
RET P07949 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486622 0.93 PDGFRA (0.72) METFLT3PDGFRAKDRAXL
SCHEMBL4489412 0.93 PDGFRA (0.72) METFLT3PDGFRAKDRAXL
SCHEMBL4495967 0.93 PDGFRA (0.72) METFLT3PDGFRAKDRAXL
SCHEMBL4481148 0.88 PDGFRA (0.81) METFLT3PDGFRAKDRAXL
SCHEMBL4482448 0.88 PDGFRA (0.81) METFLT3PDGFRAKDRAXL
SCHEMBL4487660 0.88 PDGFRA (0.81) METFLT3PDGFRAKDRAXL
SCHEMBL4480158 0.88 PDGFRA (0.60) METFLT3PDGFRAKDRAXL
SCHEMBL4487615 0.87 PDGFRA (0.70) METFLT3PDGFRAKDRAXL
SCHEMBL4494606 0.87 PDGFRA (0.70) METFLT3PDGFRAKDRAXL
SCHEMBL4482703 0.87 PDGFRA (0.70) METFLT3PDGFRAKDRAXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US claimed
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-7598258-B2 N- {4-[(6,7-dimethoxy-4-quinolyl)oxy]-2-fluorophenyll-N'-[1-(1,3-thiazol-2-yl)ethyl]urea; osteoporosis, bone metastasis of malignant tumors including breast cancer, prostatic cancer, and lung cancer, multiple myeloma, osteoporosis, Behcet's disease, rheumatoid arthritis or other diseases KIRIN BEER KABUSHIKI KAISHA (JP) 2009-10-06 US disclosed
US-20060235033-A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor KIRIN BEER KABUSHIKI KAISHA (JP) 2006-10-19 US disclosed
EP-1535910-A1 QUINOLINE DERIVATIVES AND QUINAZOLINE DERIVATIVES INHIBITING AUTOPHOSPHORYLATION OF MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR KIRIN BEER KABUSHIKI KAISHA (JP) 2005-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060235033-A1 Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of macrophage colony stimulating factor receptor CSF3R, CSF1R, MSR1 MET 26/4885FLT3 4/4885PDGFRA 137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.